PZZA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. PZZA is sitting on/just below near-term support (35.32) but the broader trend is decisively bearish (all key moving averages stacked bearishly and MACD worsening). With no proprietary buy signal today and fundamentals recently deteriorating sharply, the risk of further downside outweighs the odds of an immediate, clean rebound. For an impatient buyer, the setup is not favorable until price reclaims the pivot (37.15) and momentum stabilizes.
Trend/momentum remains bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. MACD histogram is negative (-0.101) and expanding, suggesting downside momentum is still building rather than reversing. RSI(6) at ~23.9 is deeply oversold (despite the provided label), which can produce short bounces, but oversold alone is not a buy signal when MACD and MAs are still bearish. Key levels: immediate support S1 ~35.32 (price 35.26 is slightly below it) then S2 ~34.19; resistance/pivot ~37.15, then R1 ~38.98. Pattern-based projection suggests slightly negative next day (-1.12%) but positive bias over 1 week (+3.74%) and 1 month (+6.29%)—however the current tape still favors sell-the-rip behavior until the stock regains ~37+.
Product catalyst: new Pan Pizza launch (Jan
could help traffic/mix if it resonates.
Shareholder return signal: maintained quarterly dividend at $0.46 (announced Jan 26), suggesting management confidence in cash generation.
Potential event catalyst ahead: next earnings on 2026-02-26 (pre-market) could reset the narrative if margins/comps improve.
Technical downtrend: bearish MA stack plus worsening MACD increases odds of continued drift lower, especially if ~35 and then ~34.2 fail.
Industry backdrop: analysts cite a promotional/price-war environment and pressured consumer demand, typically negative for pizza/QSR margin recovery.
Near-term setup risk: pattern stats point to a slightly negative next-day expectation; with the stock under the pivot (~37.15), rallies may get sold.
Latest reported quarter: 2025/Q3. Revenue was essentially flat (+0.27% YoY to ~$508.2M), but profitability deteriorated sharply: net income fell ~89% YoY to ~$4.45M and EPS fell ~90% YoY to $0.13. Gross margin declined to ~22.46 (down ~15% YoY). This is the key issue—top-line stability is not translating into earnings, and the market typically won’t reward the stock until margins show a durable turn.
Recent Street trend is cautious with targets being cut. In Jan 2026, BofA and Mizuho both reiterated Neutral and reduced price targets to $40 (from $42 and $44, respectively). After Q3 (Nov 2025), Stephens stayed Overweight (PT $49 from $50) and BMO stayed Outperform (PT $54 from $60), but both also cut targets due to weak comps/EBITDA and a pressured/promotional backdrop. Wall Street pros: turnaround initiatives (digital modernization, refranchising, supply chain savings) could improve FY26 execution. Cons: near-term operating pressure (soft comps, promotions) and recent margin/EPS collapse reduce confidence and keep the stock from re-rating. Influential/political flows: no recent Congress trading data and no notable insider/hedge-fund trend flagged (both neutral).
